$2.75
-0.06[-2.14%]
At close: Apr 26
$2.75
0[0.00%]
After Hours: 4:11PM EDT
Mereo BioPharma Group
(NASDAQ:MREO)Mereo BioPharma Group Stock (NASDAQ:MREO), Analyst Ratings, Price Targets, Predictions
Mereo BioPharma Group PLC has a consensus price target of $6.75, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from Needham, Cantor Fitzgerald, and Needham on April 10, 2024, March 28, 2024, and March 28, 2024. With an average price target of $6.33 between Needham, Cantor Fitzgerald, and Needham, there's an implied 130.30% upside for Mereo BioPharma Group PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Cantor Fitzgerald
SVB Leerink
BTIG
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Mereo BioPharma Group
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 118.18% | Needham | Gil Blum | → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 154.55% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 03/28/2024 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 118.18% | Needham | Gil Blum | $5 → $6 | Maintains | Buy | Get Alert |
| 03/22/2024 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 154.55% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 09/08/2023 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 45.45% | Cantor Fitzgerald | Kristen Kluska | → $4 | Reiterates | Overweight → Overweight | Get Alert |
| 09/08/2023 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 81.82% | Needham | Gil Blum | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 81.82% | Needham | Gil Blum | → $5 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 81.82% | Needham | Gil Blum | → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/26/2023 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 81.82% | Needham | Gil Blum | → $5 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2023 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 81.82% | Needham | Gil Blum | → $5 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 81.82% | Needham | Gil Blum | → $5 | Reiterates | → Buy | Get Alert |
| 11/10/2022 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 45.45% | SVB Leerink | Joseph Schwartz | $8 → $4 | Maintains | Outperform | Get Alert |
| 08/12/2022 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 45.45% | Cantor Fitzgerald | Kristen Kluska | → $4 | Initiates | → Overweight | Get Alert |
| 06/06/2022 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 81.82% | Needham | Gil Blum | $10 → $5 | Maintains | Buy | Get Alert |
| 05/05/2021 | MREO | Buy Now | Mereo BioPharma Group | $2.75 | 263.64% | BTIG | Yun Zhong | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Mereo BioPharma Group (MREO)?
The latest price target for Mereo BioPharma Group (NASDAQ: MREO) was reported by Needham on April 10, 2024. The analyst firm set a price target for $6.00 expecting MREO to rise to within 12 months (a possible 118.18% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mereo BioPharma Group (MREO)?
The latest analyst rating for Mereo BioPharma Group (NASDAQ: MREO) was provided by Needham, and Mereo BioPharma Group reiterated their buy rating.
When was the last upgrade for Mereo BioPharma Group (MREO)?
There is no last upgrade for Mereo BioPharma Group.
When was the last downgrade for Mereo BioPharma Group (MREO)?
There is no last downgrade for Mereo BioPharma Group.
When is the next analyst rating going to be posted or updated for Mereo BioPharma Group (MREO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mereo BioPharma Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mereo BioPharma Group was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Mereo BioPharma Group (MREO) correct?
While ratings are subjective and will change, the latest Mereo BioPharma Group (MREO) rating was a reiterated with a price target of $0.00 to $6.00. The current price Mereo BioPharma Group (MREO) is trading at is $2.75, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.